Siltuximab for multicentric Castleman disease

Expert Review of Hematology

Volumn 7, Issue 5, 2014, Pages 545-557

  Liu, Yi Chang ^a,b   Stone, Katie ^a   Van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Castleman disease; IL 6; monoclonal antibody; siltuximab; targeted therapy

Indexed keywords

INTERLEUKIN 6; SILTUXIMAB; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BINDING AFFINITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); ADULT; AGED; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CHEMISTRY; CLINICAL TRIAL (TOPIC); FEMALE; GIANT LYMPH NODE HYPERPLASIA; HALF LIFE TIME; HEMATOLOGIC DISEASES; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PLACEBO EFFECT; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; C-REACTIVE PROTEIN; CLINICAL TRIALS AS TOPIC; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLACEBO EFFECT; RECEPTORS, INTERLEUKIN-6; ROC CURVE; TREATMENT OUTCOME;

EID: 84907056599     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.946402     Document Type: Article

References (73)

1. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease. a systematic review of 404 published cases. Ann Surg 2012;255(4):677-84
2. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012;87(11): 997-1002
3. Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 2011;16(9):1316-24
4. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 2011;16(4): 497-511
5. van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010; 8(7):486-98
6. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol 2007;14(4):354-9
7. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129(1):3-17
8. Mehra M, Cossrow N, Stellhorn RA, et al. Use of a claims database to characterize and estimate the incidence of Castleman's disease. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 4253
9. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009;20(4):775-9
10. Robinson D Jr, Reynolds M, Casper C, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol 2014; 165(1):39-48
11. Dupin N, Diss TL, Kellam P, et al. HHV8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV8-positive plasmablastic lymphoma. Blood 2000;95(4):1406-12
12. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97(7):2130-6
13. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199-219
14. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121(9):3375-83
15. Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol 2014; 89(1):129-39
16. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22(5):347-52
17. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110(9):1911-28
18. Schulte KM, Talat N. Castleman's disease - a two compartment model of HHV8 infection. Nat Rev Clin Oncol 2010;7(9):533-43
19. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74(4):1360-7
20. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86(2):592-9
21. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20(6):304-11
22. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86(4):1276-80
23. Suda T, Katano H, Delsol G, et al. HHV8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 2001;51(9): 671-9
24. Adam N, Rabe B, Suthaus J, et al. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol 2009;83(10): 5117-26
25. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, et al. HHV8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 2012;119(22): 5173-81
26. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood 2011;118(2): 271-5
27. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 2000;96(6):2069-73
28. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2013;122(26): 4189-98
29. Dossier A, Meignin V, Fieschi C, et al. Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis 2013;56(6):833-42
30. Fajgenbaum DC, van Rhee F, Nabel CS. HHV8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014;123(19):2924-33
31. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92(3):670-6
32. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147(12): 836-9
33. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25(22):3350-6
34. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol 2011;29(18):2481-6
35. Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011;118(13): 3499-503
36. Gérard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012;119(10): 2228-33
37. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS 2008;22(13): 1685-7
38. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 2010; 116(22):4415-21
39. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009;4(1):16-21
40. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011;117(26):6977-86
41. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95(1):56-61
42. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106(8): 2627-32
43. Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006;76(2):119-23
44. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 2003;82(12):766-8
45. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005;78(4):302-5
46. Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol 2014;7(1):10
47. Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006;134(5):544-5
48. Sobas MA, Alonso Vence N, Diaz Arias J, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCDPOEMS variant). Ann Hematol 2010;89(2): 217-19
49. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 2010;9(6):1485-8
50. Galeotti C, Tran TA, Franchi-Abella S, et al. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report. J Pediatr Hematol Oncol 2008; 30(12):920-4
51. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78(5):1198-204
52. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330(9):602-5
53. Lu ZY, Brailly H, Wijdenes J, et al. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995;86(8): 3123-31
54. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9(13):4653-65
55. van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998; 102(3):783-90
56. van Zaanen HC, Koopmans RP, Aarden LA, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feedback loop. J Clin Invest 1996;98(6):1441-8
57. Sylvant. SylvantTM (siltuximab) for injection [package insert]. Janssen Biotech, Inc; Horsham, PA, USA: 2014. Available from: www. sylvant. com [Last accessed 8 July 2014]
58. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19(13):3659-70
59. Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116(18):3627-34
60. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008; 14(11):3262-7
61. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28(23):3701-8
62. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2014 july 17. pii: S1470-2045(14)70319-5. doi: 10. 1016/S1470-2045(14)70319-5. [Epub ahead of print]
63. Markham A, Patel T. Siltuximab: first global approval. Drugs 2014;74:1147-52
64. Kirk M, Kurzrock R, van Rhee F, et al. Siltuximab reverses muscle wasting in patients with multicentric Castleman's disease. Blood (ASH Annual Meeting Abstracts) 2013;122(21):abstract 4394
65. van Rhee F, Casper C, Voorhees PM, et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman's disease. Blood (ASH Annual Meeting Abstracts) 2013;122(21):abstract 1806
66. Thomas SK, Suvorov A, Noens L, et al. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 2014;73(1):35-42
67. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHVMCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol 2012;3:73
68. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol 2012; 24(5):495-505
69. Tocilizumab for KSHV-associated multicentric Castleman disease. Available from: www. clinicaltrials. gov/ct2/results? term=NCT01441063&Search=Search
70. CDCN. Available from: www. castlemannetwork. org
71. Williams SC. First IL-6-blocking drug nears approval for rare blood disorder. Nat Med 2013;19(10):1193
72. Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;161(3):357-66
73. San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014;123(26):4136-42